Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding

Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube through...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Enteral Nutrition I: Orogastric and Nasogastric Feeding

Enteral Nutrition I: Orogastric and Nasogastric Feeding

Enteral nutrition delivers nutrients directly to the stomach or small intestine through a tube. This method is appropriate for patients who cannot eat but still have a functioning digestive system. It is also beneficial for individuals with swallowing difficulties, anorexia, malabsorption, or those who have undergone gastrointestinal (GI) surgery.
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...

Drug Delivery: Enteral Route

Drug Delivery: Enteral Route

The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...

Routes of Drug Administration: Enteral

Routes of Drug Administration: Enteral

Medications can be administered through the enteral route using liquids, capsules, or tablets.
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effect of Inpatient Pharmacist-Led Medication Reconciliations on Medication-Related Interventions in Intensive Care Unit Recovery Centers.

Hospital pharmacy·2024

Same author

An international, multicenter post hoc analysis comparing in-person and virtual medication management strategies in post-ICU recovery clinics.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024

Same author

Characteristics Contributing to a Pharmacy Services Excellence Model in a Large Health System.

HCA healthcare journal of medicine·2023

Same author

COVID-19: The Vaccine Race Continues.

HCA healthcare journal of medicine·2023

Same author

Innovative Conservation of Inhaled Medication Devices During the COVID-19 Pandemic Through a Canister Reassignment Process.

HCA healthcare journal of medicine·2023

Same author

Covid-19: Race For A Vaccine.

HCA healthcare journal of medicine·2023

Search research articles

Related Experiment Video

Updated: Jul 7, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Interaction between levodopa and enteral nutrition.

Mandelin K Cooper¹, David G Brock, Cara M McDaniel

¹Department of Pharmacy, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

The Annals of Pharmacotherapy

|February 15, 2008

Summary

High protein enteral nutrition can reduce levodopa effectiveness in Parkinson's disease patients. Adjusting protein content and feeding method improved symptom control, highlighting a critical drug-nutrient interaction.

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: Jul 7, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Clinical Pharmacy
Nutritional Science
Neurology

Background:

Levodopa is a primary medication for Parkinson's disease (PD).
Enteral nutrition is crucial for nutritional support in critically ill patients.
Protein intake is known to interact with levodopa absorption in ambulatory patients.

Observation:

A 77-year-old male with PD experienced worsening parkinsonian symptoms despite continuous medication.
The patient was receiving high-protein (1.4 g/kg/day) continuous enteral nutrition.
Parkinsonian symptoms improved significantly after reducing protein and changing to bolus enteral feeding.

Findings:

A probable drug-nutrient interaction between protein in enteral nutrition and levodopa was identified.
Continuous enteral feeding and high protein content likely impaired levodopa absorption.
Modifying enteral nutrition delivery and content resolved the interaction and improved symptom control.

Implications:

Clinicians must consider protein content and administration method of enteral nutrition in PD patients on levodopa.
This interaction may be underrecognized in critically ill patients receiving tube feeds.
Awareness and proactive management are essential for optimizing levodopa efficacy in this population.